BIODESIX, INC. (BDSX) Current Ratio
- Current ratio · latest quarter: Value 2.85×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.85× | Current assets / current liabilities. $43.56M ÷ $15.29M ≈ 2.85× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 43.56M USD | Assets, Current |
| Current obligations | 15.29M USD | Liabilities, Current |
| Cash and equivalents | 30.00M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 9.11M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 2.16M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $43.56M | $15.29M | $30.00M | (m) | $9.11M | (m) | $2.16M | (m) | 2.85× |
| 2026-03-31 | $40.91M | $14.49M | $25.57M | (m) | $9.50M | (m) | $3.65M | (m) | 2.82× |
| 2025-12-31 | $32.52M | $17.44M | $18.99M | (m) | $9.04M | (m) | $3.08M | (m) | 1.86× |
| 2025-09-30 | $33.40M | $18.15M | $16.60M | (m) | $12.67M | (m) | $3.62M | (m) | 1.84× |
| 2025-06-30 | $32.45M | $15.16M | $20.73M | (m) | $7.45M | (m) | $2.97M | (m) | 2.14× |
| 2025-03-31 | $29.62M | $13.32M | $17.60M | (m) | $7.64M | (m) | $2.92M | (m) | 2.22× |
| 2024-12-31 | $39.48M | $14.32M | $26.25M | (m) | $8.60M | (m) | $2.19M | (m) | 2.76× |
| 2024-09-30 | $44.02M | $12.96M | $31.41M | (m) | $8.04M | (m) | $2.54M | (m) | 3.40× |
| 2024-06-30 | $57.58M | $17.55M | $42.22M | (m) | $10.13M | (m) | $2.22M | (m) | 3.28× |
| 2024-03-31 | $28.48M | $31.23M | $11.49M | (m) | $9.89M | (m) | $3.21M | (m) | 0.91× |
| 2023-12-31 | $39.68M | $33.42M | $26.28M | (m) | $7.68M | (m) | $2.93M | (m) | 1.19× |
| 2023-09-30 | $28.89M | $32.65M | $19.84M | (m) | $5.78M | (m) | $2.90M | (m) | 0.88× |
| 2023-06-30 | $25.25M | $27.95M | $17.41M | (m) | $4.12M | (m) | $3.50M | (m) | 0.90× |
| 2023-03-31 | $34.78M | $22.10M | $25.27M | (m) | $4.90M | (m) | $1.56M | (m) | 1.57× |
| 2022-12-31 | $53.33M | $22.84M | $43.09M | (m) | $5.07M | (m) | $1.69M | (m) | 2.34× |
| 2022-09-30 | $24.12M | $37.41M | $15.18M | (m) | $4.45M | (m) | $2.10M | (m) | 0.64× |
| 2022-06-30 | $35.06M | $33.07M | $23.59M | (m) | $5.45M | (m) | $1.79M | (m) | 1.06× |
| 2022-03-31 | $27.23M | $29.81M | $16.43M | (m) | $3.77M | (m) | $2.12M | (m) | 0.91× |
| 2021-12-31 | $43.61M | $28.96M | $32.71M | (m) | $3.66M | (m) | $1.66M | (m) | 1.51× |
| 2021-09-30 | $56.45M | $22.79M | $47.91M | (m) | $2.78M | (m) | $1.60M | (m) | 2.48× |
| 2021-06-30 | $68.45M | $21.27M | $56.35M | (m) | $5.28M | (m) | $1.16M | (m) | 3.22× |
| 2021-03-31 | $81.24M | $16.12M | $55.33M | (m) | $18.37M | (m) | $3.75M | (m) | 5.04× |
| 2020-12-31 | $86.14M | $32.13M | $62.13M | (m) | $15.30M | (m) | $8.96M | (m) | 2.68× |
| 2020-09-30 | $18.15M | $56.56M | $6.35M | (m) | $5.40M | (m) | $3.48M | (m) | 0.32× |
| 2019-12-31 | $12.70M | $22.60M | $5.29M | (m) | $5.29M | (m) | $1.72M | (m) | 0.56× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |